Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPIC
2024-512001-39-01Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary infection and bacterial pneumonia comparing Infectomox (amoxicillin) arm with Placebo arm (2 arms). Primary endpoint: Therapy failure by day 21. Planned start Dec 2024; status: authorised.
02
Drugs
amoxicillin
03
Conditions
pulmonary infectionbacterial pneumonia
Beyond the preview
Go deeper on 2024-512001-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512001-39-01.